… growth factor (EGF) belongs to a family of related peptides (EGF-like growth factor), which
include transforming growth factor o (TGFo… EGF-like growth factors bind to activate one or more …

… of rash during treatment with the epidermal growth factor receptor inhibitor erlotinib and
improved … (single agent in non–small-cell lung cancer, n = 444 in erlotinib group and n = 229 in …

… Erlotinib (Tarceva®) has demonstrated a survival benefit in … erlotinib, epidermal growth
factor receptor (EGFR) protein expression may provide a basis for selecting patients for treatment …

… from tissue resected 68 days after the initiation of erlotinib treatment, after the patient was
off study and no longer treated with erlotinib. There was not sufficient tissue to complete all …

… to undergo erlotinib treatment were … start of erlotinib treatment can identify erlotinib responders
and nonresponders. These findings are relevant because early identification of treatment …

… Role of IGF-IR signaling pathways in the development of resistance to erlotinib treatment
in NSCLC cells. To investigate the mechanisms involved in the sensitivity of NSCLC cells to …

… cell carcinoma; erlotinib; gefitinib; and epidermal growth factor receptor were combined with
… cell lung; Iressa; gefitinib; ZD1839; Tarceva; erlotinib; OSI774; and EGFR-TK. These terms …

… Most adverse events associated with erlotinib plus gemcitabine treatment in this study
were mild-to-moderate, consistent with previous studies [2-5]. Rash was more frequent with …

… In summary, potentiation of the antitumor efficacy of distinct classes of growth factor
receptor inhibitors by erlotinib may have important clinical implications for the treatment of …

… Erlotinib (Tarceva) is an orally available HER1 (epidermal growth factor receptor, EGFR)
tyrosine kinase inhibitor advancing through clinical trials for the treatment of a range of human …